American Urological Association Names New Officers and Board Members
Lane Palmer, MD, will serve as the 2025-2026 AUA president, having served as president-elect since May 2024. Dr. Palmer has served as chair of the AUA-SPU Task Force on Intersex and Transgenderism which has been instrumental in deterring efforts in passing legislation which would ban surgery on children with Intersex conditions during childhood and is a past-president of the AUA New York Section. He is currently a Professor of Urology and Pediatrics at the Zucker School of Medicine at Hofstra/Northwell and Chief of Pediatric Urology at Cohen Children's Medical Center of New York at Northwell Health.
Eugene Y. Rhee, MD, MBA, has been named AUA 2025-2026 president-elect. Dr. Rhee served as AUA Public Policy chair from 2020 to 2024, was a graduate of the AUA Leadership Program and a distinguished AUA Gallagher Health Policy Scholar. Dr. Rhee currently holds dual leadership roles as Chief of Urology for Kaiser Permanente Southern California and Area Assistant Medical Director for Business Line & Finance for Kaiser Permanente San Diego.
Stephen Y. Nakada, MD, FACS, FRCS, is now the immediate past president of the AUA. Dr. Nakada served as the AUA president from 2024 to 2025. He has also been President of the R.O.C.K. Society, the Society of Academic Urologists, the Endourological Society and the American Board of Urology. Dr. Nakada is currently a professor and chairman of the Department of Urology, and the David T. Uehling chair of Urology at the University of Wisconsin School of Medicine and Public Health in Madison, WI.
Jennifer U. Miles-Thomas, MD, MBA, joins the AUA Board as Treasurer this year, serving as Treasurer-elect 2024-2025. Dr. Miles-Thomas has served as a mentor in the AUA Leadership Program, contributed to the AUA Leadership & Business Education Committee, hosted multiple AUA podcasts focused on the Business of Urology and sat on the Mid-Atlantic AUA Board of Directors. She is currently the Vice Chair of Regional Integration and Innovation in the Department of Urology at Northwestern Medicine.
Adam S. Kibel, MD, MHCM, joins the Board as the New England Section Representative. His leadership positions include serving on the AUA Quality Council, the NCCN-Prostate Screening Guidelines Committee, the NCI Genitourinary Trial Steering Committee, the CALGB Executive Committee and President-elect of the Society of Urologic Oncology. Dr. Kibel is currently the chair of Urology at Mass General Brigham, the Elliott Carr Cutler professor of surgery at Harvard University, the DiNovi chair of Urology at BWH, the chair of the Harvard Residency Program (BWH) and Disease Center co-leader of the Dana Farber GU Oncology Program.
Ronald P. Kaufman Jr., MD, joins the Board as the Northeastern Section Representative. Dr. Kaufman was a member of the inaugural AUA Leadership Program in 2004, was chair of the AUA Coding and Reimbursement Committee, served as a consultant to the AMA Current Procedural Terminology (CPT) Editorial Panel and is a past president of the New York State Urological Society and the Northeastern Section of the AUA. He is currently a Professor of Surgery in the Department of Urology at Albany Medical College in Albany, New York.
The AUA would like to recognize and thank the Board members whose terms concluded on April 30, 2025. Randall Meacham, MD, has completed his years of presidential service along with regional Section Representatives, Arthur Tarantino, MD, from New England, Hassan Razvi, MD, from Northeastern, and former Treasurer, Thomas Stringer, MD.
A full list of AUA Board members is now available at https://www.auanet.org/about-us/leadership/board-of-directors.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology and has nearly 26,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
Attachment American Urological Association Names New Officers and Board Members
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Veradigm Amends and Extends Stockholder Rights Plan
CHICAGO, August 20, 2025--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan for an additional six months (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire at 5:00PM New York City time on August 20, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to February 20, 2026. In addition, the amendment to the Rights Plan changes the triggering threshold such that the rights would become exercisable only if a person or group acquires beneficial ownership of 20% or more of the outstanding shares of Company common stock (including in the form of synthetic ownership through derivative positions) in a transaction not approved by the Board, whether or not such person or group is an eligible passive investor. The Board's decision to extend the Rights Plan is based on its determination that many of the underlying risks and conditions that existed upon the initial adoption of the Rights Plan continue to be present. Accordingly, the Rights Plan is being extended to continue to ensure that all Veradigm stockholders have the opportunity to realize the full potential value of their investment. The Rights Plan does not prevent the Company from pursuing any offer that is fair and otherwise in the best interests of stockholders. The Board currently intends to terminate the Rights Plan no later than the time that the Company becomes current in its financial reporting and has applied for relisting of its shares of common stock on a national stock exchange, which is expected to occur in 2026. Further details about the Rights Plan, as amended, will be contained in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or Company names are the property of their respective holders, all rights reserved. Disclaimer and Forward-Looking Statement Information This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the Company's expectations with respect to the timing of the relisting of its common stock on a national securities exchange. These forward-looking statements are based on the current beliefs and expectations of the Company's management with respect to future events, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as "future," "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "will," "would," "could," "continue," "can," "may," "look forward," "aims," "hopes," and "seeks" and similar terms, although not all forward-looking statements contain such words or expressions. Actual results could differ significantly from those set forth in the forward-looking statements. Important factors that may cause actual results to differ materially from those in the forward-looking statements include, among others: a further material delay in the Company's financial reporting or ability to hold an annual meeting of stockholders; an inability of the Company to timely prepare its delinquent financial statements; unanticipated factors or factors that the Company currently believes will not cause further delay; the Company's remediation efforts and preparation of financial statements or other factors that could cause additional delay or adjustments; the possibility that ongoing remediation work or the audit of the Company's financial statements for the fiscal year ended December 31, 2023 or the fiscal year ended December 31, 2024 may identify additional errors and material weaknesses or other deficiencies in the Company's accounting practices; the likelihood that the control deficiencies identified or that may be identified in the future will result in additional material weaknesses in the Company's internal control over financial reporting; risks relating to the Company's voluntary disclosure to the SEC of certain information relating to the investigation by the Audit Committee of the Company's Board of Directors, the SEC's investigation, and the additional information the Company has continued to provide to the SEC based on discussions with the SEC; changes in the financial condition of the markets that the Company serves; the Company's ability to hire qualified individuals to serve in senior leadership roles on a permanent basis, including a chief financial officer; and other factors contained in the "Risk Factors" section and elsewhere in the Company's filings with the SEC from time to time, including, but not limited to, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The Company does not undertake to update any forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes over time, except as required by law. View source version on Contacts For more information contact: Investors:Jenny Media:Rick Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
3 days ago
- Medscape
Kids Feel Less Pain With Underused Kidney Stone Treatment
Shockwave lithotripsy (SWL) for pediatric patients leads to less pain and fewer abnormal urinary symptoms after recovery than the widely used ureteroscopy (URS) procedure, according to research published in JAMA Network Open . Researchers and other urologists said the findings confirm what they have observed: Fewer children and teens complain of pain and other symptoms in the days after the SWL than the URS, despite similar efficacy rates of each treatment. The incidence of kidney stones has risen in the past few decades, with the majority of these cases receiving URS. 'Patients are increasingly faced with this question of which procedure to choose and have very little information to guide them,' said Gregory Tasian, MD, director of the Pediatric KIDney Stone Care Improvement Network at Children's Hospital of Philadelphia, Philadelphia, and lead author of the study. 'All of the information that existed has been based on the ability to clear stones, which is important but doesn't account for other factors that patients and their parents find really important.' The researchers undertook the study to gather more robust evidence for treatment protocols, Tasian said. Caregivers and patients were included in initial planning to determine relevant outcomes, including the measures of pain intensity and missed school, he said. In a nonrandomized clinical trial, 1142 patients aged 8-21 years completed a questionnaire 1 week after their procedure. Those who received the shockwave procedure reported an average pain intensity score of 42.8 on a 56-point scale, about 7 points lower than for those who underwent URS. Scores for pain interference with daily life in the shockwave group averaged 10 points lower than among the URS group. Stones were cleared in 71% of patients who received URS and about 68% of those who received SWL. Average patient scores on a questionnaire assessing difficult and uncontrollable urination were about 4 points lower in the SWL group than in the URS group. Patients who received SWL also missed 21% fewer school days, and their parents missed 23% fewer workdays than those who received URS. The study took place between 2020 and 2023 at 31 medical centers in the US and Canada. The majority of the population was women (60%) and White (77%). 'We learned from this research that pain is much greater with ureteroscopy, as are urinary symptoms,' said Tasian. 'And that really drives the patient experience.' The American Urological Association (AUA) currently recommends URS and SWL equally for stones < 20 mm. But the guidance is based on low-level certainty evidence that does not include studies on patient experience, including pain levels. The more frequent use of ureteral stents — tubes used to open and drain the urethra — in URS may account for the higher pain levels and disruptions to daily life, Tasian said. Patients in the study undergoing URS needed a stent 80% of the time compared with 2.6% of those undergoing SWL and were 10 times more likely to need an additional surgery under general anesthesia to remove the stent. Many hospitals do not have the lithotripter needed for the shockwave procedure, said Renea Sturm, MD, an assistant professor of pediatric urology at UCLA Health, Los Angeles, and an author of the study. As a result, 'real-world implementation of the treatment may be a bit challenging,' Sturm said. 'I think a lot of us will want to change our practice, and this research helps us argue with the larger system' to purchase the equipment, said Kathleen Kan, MD, pediatric urologist at Stanford Medicine Children's Health in Los Gatos, California, who was not involved in the study. She said that her patients who receive SWL are less likely to message her afterward with complaints of pain. New AUA kidney stone guidelines are currently in development and expected to be released in 2026, a spokesperson for AUA said. The study was funded by the Patient-Centered Outcomes Research Institute (PCORI). Kan and Sturm reported having no disclosures. Tasian reported receiving grants from the PCORI.
Yahoo
3 days ago
- Yahoo
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to Executive Leadership Team
Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Coloplast Group strategy. Over the last couple of months, senior leaders from across the Coloplast Group have worked together to finalise the new Coloplast Group strategy, which will be communicated internally and externally in early September following approval by the Board of Directors. 'Our new strategy is centered around our customers. We will create and deliver the best customer experience for our users, patients and clinicians across our offering of products, support and services. Our ambition is to set the standard of care, to lead the market and to win!' says Lars Rasmussen, interim CEO of Coloplast. 'To deliver value for our customers, shareholders and more, we must evolve. That means putting the customer at the centre of everything we do. It also means delivering a step change in innovation to solidify our position as the innovation leader in our industry,' says Lars. During the current strategy period, the Coloplast Group has expanded with the addition of Atos Medical and Kerecis. Effective immediately, the company will organise its businesses into two distinct business units: Chronic Care and Acute Care. This structure allows the company to respect the differences in market dynamics, customer needs, patient pathways and business models, and it creates the needed structure to execute on the company's 2030 strategy. Changes to Chronic CareEffective immediately, a new Chronic Care Commercial business unit is being established. This will include the existing Chronic Care sales regions as well as relevant Chronic Care commercial functions. Given the chronic nature of most patients served by Atos Medical, the Voice & Respiratory Care business, Atos will also become part of the new Chronic Care Commercial business unit. To deliver a step change in innovation and bring new products faster to market, a stand-alone Chronic Care R&D function is also being established. 'As we are making significant changes to the Chronic Care setup, the Board and Executive Vice President Nicolai Buhl have mutually agreed that Nicolai will leave Coloplast. Nicolai has achieved great things in his time with Coloplast as a senior leader within Wound Care as well as Chronic Care. On behalf of the Board and the ELT, I want to thank Nicolai for his dedication and leadership,' says Lars. Caroline Vagner Rosenstand will take on the role as Executive Vice President of Chronic Care Commercial. 'Caroline is an experienced leader with a great track record of building followership, defining and executing on commercial strategies and delivering results,' says Lars. On November 1st, Rasmus Just will step into the role of Executive Vice President of Chronic Care R&D. Rasmus Just brings valuable experience from his five years at Coloplast, where he held several leadership roles within innovation, before continuing his career for the past 3 years in Device R&D at Novo Nordisk. 'Rasmus is an experienced R&D leader with a strong technology and business focus, and we are happy to welcome him back to Coloplast,' says Lars. Introducing Acute CareThe new Acute Care business unit includes Interventional Urology (IU), Advanced Wound Dressings (AWD) and Kerecis. These treatment areas are characterised by premium products like Coloplast's penile implants, the Kerecis fish skin portfolio and our wound dressings. Most of these products and technologies are used in specialised private clinics or in the hospital setting, where innovation and clinical outcomes are critical. Effective immediately, the AWD and Kerecis commercial organisations are being merged into a new Wound & Tissue Repair organisation within Acute Care. The goal is to become an innovation leader in this area and to create a strong global footprint by merging these two complementary businesses. Wound & Tissue Repair will be led by Executive Vice President Fertram Sigurjonsson. 'With Kerecis, Fertram has built a company with strong innovation capability and growth potential based on a unique technology. Bringing these capabilities together in a new Wound & Tissue Repair unit represents a significant milestone for our AWD and Kerecis businesses,' says Lars. There are no changes to the IU business, which will continue under the leadership of Executive Vice President Tommy Johns. 'I would like to congratulate Caroline, Fertram and Rasmus on their new roles,' ends Lars. The new ELT Lars Rasmussen, interim CEO Anders Lonning-Skovgaard, EVP & CFO Allan Rasmussen, EVP Global Operations Dorthe Rønnau, EVP People & Culture Caroline Vagner Rosenstand, EVP Chronic Care Commercial Rasmus Just, EVP Chronic Care R&D (start date 1 November) Fertram Sigurjonsson, EVP Wound & Tissue Repair Tommy Johns, EVP Interventional Urology Lars Rasmussen, interim President and CEO, and Anders Lonning-Skovgaard, Executive Vice President and CFO, constitute the management registered with the Danish Business Authority. ContactsPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@ Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 2458Email: dkadim@ Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 3266Email: dkkhu@ Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 2981Email: dksdk@ This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound and Skin Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, 05_2025_Coloplast_announces_changes_to_ELTSign in to access your portfolio
